Excipient Applications in Formulation Design and Drug Delivery 2015
DOI: 10.1007/978-3-319-20206-8_12
|View full text |Cite
|
Sign up to set email alerts
|

Selection of Excipients Based on the Biopharmaceutics Classification System of Drugs

Abstract: Active agents have been considered the main ingredients of any therapeutic product since the early ages of formulation technology. However, the importance of the inactive ingredients has been realized during the last three decades. With the development and manufacturing of more intelligent and multifunction excipients, new ways became available for formulation technologists to increase the beneficial effects of drugs on human body. Many modern active agents have internal characteristics that significantly decr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 100 publications
0
1
0
Order By: Relevance
“…4,5 According to the biopharmaceutical classification system (BCS), adopted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the basis for granting API biowaivers, 6,7 drugs included in class II present high permeability but low aqueous solubility, which impacts their oral bioavailability. [8][9][10] Many researchers have proven that by inducing structural modifications in the API solid forms, it is possible to increase the aqueous solubility and dissolution rate of drugs while maintaining their biological activity. [11][12][13][14] Among the referred structural modifications, cocrystal formation has emerged in the past two decades as an attractive way to modify the desired physicochemical properties since they allow crystalline structure modifications without making and/or breaking covalent bonds.…”
Section: Introductionmentioning
confidence: 99%
“…4,5 According to the biopharmaceutical classification system (BCS), adopted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the basis for granting API biowaivers, 6,7 drugs included in class II present high permeability but low aqueous solubility, which impacts their oral bioavailability. [8][9][10] Many researchers have proven that by inducing structural modifications in the API solid forms, it is possible to increase the aqueous solubility and dissolution rate of drugs while maintaining their biological activity. [11][12][13][14] Among the referred structural modifications, cocrystal formation has emerged in the past two decades as an attractive way to modify the desired physicochemical properties since they allow crystalline structure modifications without making and/or breaking covalent bonds.…”
Section: Introductionmentioning
confidence: 99%